Aurum Stibium Hyoscyamus
Generic Name: aurum stibium hyoscyamus
Brand Names:
Aurum Stibium Hyoscyamus
Use: Temporary relief of headache.
Overview
Use: Temporary relief of headache.
Uses
Directions: FOR ORAL USE ONLY.
Dosage
Take 3-4 times daily. Ages 12 and older: 10 drops. Ages 2-11: 5 drops. Under age 2: Consult a doctor.
Warnings
Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions or if conditions worsen or persist. If pregnant or nursing consult a doctor before use. Do not use if safety seal is broken or missing.
Frequently Asked Questions
What is Aurum Stibium Hyoscyamus used for?▼
Directions: FOR ORAL USE ONLY.
What are the important warnings for Aurum Stibium Hyoscyamus?▼
Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions or if conditions worsen or persist. If pregnant or nursing consult a doctor before use. Do not use if safety seal is broken or missing.
Related Medications
Camouflage Chlorpheniramine
camouflage chlorpheniramine
Dosage form: POWDER. Active ingredients: CHLORPHENIRAMINE (1 kg/kg). Category: BULK INGREDIENT.
Pancrelipase Lipase, Pancrelipase Protease, Pancrelipase Amylase
pancrelipase lipase, pancrelipase protease, pancrelipase amylase
11 DESCRIPTION Pancrelipase is a pancreatic enzyme product consisting of a mixture of enzymes including lipases, proteases, and amylases, and is an extract derived from porcine pancreatic glands. The enteric-coated pellets in ZENPEP are formulated to release pancreatic enzymes at an approximate pH of 5.5 or greater. ZENPEP (pancrelipase) delayed-release capsule for oral administration, include a two-piece shell containing light brown-colored enteric-coated pellets (1 .
Anifrolumab-fnia
anifrolumab-fnia
Type I Interferon Receptor Antagonist [EPC]
11 DESCRIPTION Anifrolumab-fnia is a type I interferon (IFN) receptor antagonist, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is produced in mouse myeloma cells (NS0) by recombinant DNA technology. The molecular weight is approximately 148 kDa. SAPHNELO (anifrolumab-fnia) injection is a sterile, preservative‑free, clear to opalescent, colorless to slightly yellow, solution for intravenous use. SAPHNELO contains anifrolumab-fnia at a concentration of 150 mg/mL in a single-dose vial.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.